Harrow Health Inc HROW

NAS: HROW | ISIN: US4158581094 30/04/2025

24,77 USD (+0,41%)

(+0,41%) 30/04/2025

Toon enkel gratis nieuws

24 april 2025 · NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) · Persbericht

1 april 2023 · HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options · Persbericht

28 maart 2023 · B. Riley Leads Financing to Support Harrow Health Acquisition · Persbericht

18 maart 2023 · HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options · Persbericht

11 maart 2023 · HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options · Persbericht

8 maart 2021 · Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results · Persbericht

9 februari 2021 · Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe